Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, ...

Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...

An Australian research collaboration has led to a major leap forward in the treatment of acute lymphoblastic leukemia (ALL). Recently published clinical trial results have shown evidence that ...

A South Coast teenager is in the fight of his life, and his mother is appealing to the public to help by registering to become bone marrow donors.

Amgen acquires Dark Blue Therapeutics to fight Acute Myeloid Leukemia. See how this $840M deal aims to deliver first-in-class ...

Just three days after Syndax Pharmaceuticals revealed data from a trial of revumenib in one indication of acute leukemia which chilled investors, the FDA has approved the small molecule in another ...

The diagnosis of acute leukaemia in children, most notably acute lymphoblastic leukaemia (ALL), remains a critical challenge in paediatric medicine. A significant proportion of patients present with ...

Medications for AML include chemotherapy and newer targeted therapies. With several options available, the right medication for you will depend on the specific characteristics of your cancer. Acute ...

Patients with acute leukemia prioritize tiredness as the most important health dimension over cognition, differing from the general public's preferences. Informal caregivers report significant ...

Credit: Getty Images ALL is the most common childhood cancer, and cases are rising. Find out why this trend is paired with a remarkable 90% survival rate, and what public health action is needed next.

Gyala Therapeutics initiates phase I/IIa trial of a CAR-T cell therapy for acute leukaemias with limited treatment: Barcelona, Spain Wednesday, February 11, 2026, 18:00 Hrs [IST] ...